Abstract 26P
Background
Subcutaneous (SC) trastuzumab offers a distinctive approach to treat HER2-positive breast cancer in contrast with conventional intravenous (IV) infusion. SC can be administered at day care unit, which is potentially a big step forward with a more efficient treatment mode compared to IV administration at inpatient wards. This study aimed to quantify the impact of treatment mode transition by measuring its benefits to hospitals as well as patients in China.
Methods
This time-motion study was conducted in Tianjin Medical University Cancer Institute & Hospital, where breast cancer treatment mode was shifted from IV administration at inpatient ward to SC administration at day care unit. The duration of each specific task conducted by HCPs and the time patient spent were recorded by observers. Costs, including HCP salaries, medical consumables, and other relevant items, were collected from public sources. The study outcomes included hospital capacity improvements, time savings for HCPs, and cost reductions for hospital. Meanwhile, patients' time savings and cost of lost labor were also measured.
Results
The treatment mode transition significantly improved the hospital operation efficiency. For 80 patients visited per day, IV administration required 80 inpatient beds, but SC administration in day care unit only occupied 6 injection chairs, equals to a freeing up of around 24,960 bed-days annually for a hospital. Considering this optimized and reallocated inpatient resources, estimated potential benefits were CNY 68,902 per day and CNY 21,497,490 per year. In addition, the adoption of SC administration reduced nursing working hour by 81%. For patients and caregivers, the treatment time per cycle was 91% less than IV administrations, leading to total savings of CNY 19,681 per patient in terms of direct cost and productivity cost over a full course of treatment.
Conclusions
Besides saving time for HCPs and patients, trastuzumab SC can help optimize treatment process, improve overall quality and efficiency of healthcare system & hospital management, aligned with China policies of high-quality hospital development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Medical University Cancer Institute & Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract